| Literature DB >> 25194571 |
Daphne A Stanley1, Anna N Honko2, Clement Asiedu3, John C Trefry4, Annie W Lau-Kilby1, Joshua C Johnson2, Lisa Hensley2, Virginia Ammendola5, Adele Abbate5, Fabiana Grazioli5, Kathryn E Foulds1, Cheng Cheng1, Lingshu Wang1, Mitzi M Donaldson1, Stefano Colloca5, Antonella Folgori5, Mario Roederer1, Gary J Nabel6, John Mascola1, Alfredo Nicosia7, Riccardo Cortese8, Richard A Koup1, Nancy J Sullivan1.
Abstract
Ebolavirus disease causes high mortality, and the current outbreak has spread unabated through West Africa. Human adenovirus type 5 vectors (rAd5) encoding ebolavirus glycoprotein (GP) generate protective immunity against acute lethal Zaire ebolavirus (EBOV) challenge in macaques, but fail to protect animals immune to Ad5, suggesting natural Ad5 exposure may limit vaccine efficacy in humans. Here we show that a chimpanzee-derived replication-defective adenovirus (ChAd) vaccine also rapidly induced uniform protection against acute lethal EBOV challenge in macaques. Because protection waned over several months, we boosted ChAd3 with modified vaccinia Ankara (MVA) and generated, for the first time, durable protection against lethal EBOV challenge.Entities:
Mesh：
Substances：
Year: 2014 PMID： 25194571 DOI： 10.1038/nm.3702
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440